Special Issue "Neuroactive Compounds"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (31 December 2010)
Dr. Maurice Tangui
INSERM U. 710, University of Montpellier 2, 34095 Montpellier cedex 5, France
Research in Neuroscience has never been so active, taking benefits from recent developments in functional imaging, molecular biology and transgenesis, or improvements in animals’ cognitive behavioral analyses. Paradoxically, validation of new therapeutic strategies and marketing of really innovative medicine against pathologies with major social issues like Alzheimer’s disease and related neurodegenerative disorders, ischemic insults, depression, or schizophrenia mark time and do not find way out in a near future. Drug development pipelines of pharmaceutical companies remain alarmingly empty.
This combined Special Issue of Molecules and Pharmaceuticals, on Neuroactive Compounds, will offer an unique forum to present the chemistry, pharmacology and therapeutic opportunities offered by new and innovative molecular series in all areas of neuropharmacology and neuroscience. I strongly encourage authors to submit papers for this special issue, within the scope of Molecules and Pharmaceuticals, and I hope that the fields covered will allow to rise our hopes in seeing soon the validation of breakthrough treatments in central pathologies of major concern.
Dr. Tangui Maurice
Related Special Issues
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- psychoactive drugs
- neuroprotective agents
- anti-stress drugs
- brain imaging tools
- brain penetration
- blood-brain barrier agents
Review: Nanomedicine Faces Barriers
Pharmaceuticals 2010, 3(11), 3371-3416; doi:10.3390/ph3113371
Received: 31 August 2010; in revised form: 5 October 2010 / Accepted: 25 October 2010 / Published: 28 October 2010| Download PDF Full-text (916 KB)
Review: Neuroactive Multifunctional Tacrine Congeners with Cholinesterase, Anti-Amyloid Aggregation and Neuroprotective Properties
Pharmaceuticals 2011, 4(2), 382-418; doi:10.3390/ph4020382
Received: 29 December 2010; in revised form: 3 February 2011 / Accepted: 12 February 2011 / Published: 18 February 2011| Download PDF Full-text (381 KB) | Download XML Full-text
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Type of Paper: Review
Title: NBM-T-L-BMX-OS01, a Novel Histone Deacetylase Inhibitor (HDACi) has a Potent Neuroprotective Effects in MPTP-Induced Parkinson’s Disease Model
Authors: Ying-C Yang1, Wei-Jan Huang2, Yu-Chen Huang3, Chung-Yang Huang3, Chia-Nan Chen3
Affiliation: 1Department of Animal Science, National I-Lan University, I-Lan, Taiwan
2Graduate Institute of Pharmacognosy, College of Medicine, Taipei Medical University, Taipei 110, Taiwan
3NatureWise Biotech and Medicals Corporation, Taipei 115, Taiwan; E-Mail: email@example.com
Abstract: Epigenetic changes are key factors controlling several gene expressions and are known to be correlated with many neural processes, neurodegenerative diseases and cancer. There is increasing evidence demonstrated that histone deacetylase inhibitor (HDACi) can possess neuroprotective effects via several of mechanisms. Previously, we investigated a novel HDAC8-specific inhibitor was identified from our laboratory, termed NBM-T-L-BMX-OS01 (BMX). This agent was derived from the semi-synthesis of osthole, isolated from Cnidium monnieri (L.) Cuss., and was shown to be a potent suppressor for tumor growth in xenograft model and markedly improving the learn and memory in Morris Water Maze task. In this present study, we found that pre-treatment with BMX can efficiently prevention of MPTP (1-methyl-4-phenyl-1, 2. 3, 6-tetrahydropyridine)-induced a parkinsonian syndrome. Furthermore, we were interesting whether BMX can be used for the therapy of Parkinson’s disease. Mice were injected intraperitoneally (ip) with MPTP (30 mg/kg) or without MPTP (control group) once daily for 7 days to induce a sub-acute state then randomized into three groups. Three groups of MPTP-induced parkinson’s disease mice were treated with compounds or without (negative control group). Compounds, BMX (BMX group) and SAHA (suberoylanilide hydroxamic acid, a noted pan-HDAC inhibitor) (SAHA group) were injected ip with the same dose (5 mg/kg) into mice once daily for 7 days then determined the neuroprotective effects by using the rotary. Our data demonstrated that BMX group and SAHA group mice compared with negative control group mice were exert a significantly neuroprotective effects in MPTP-induced Parkinson’s disease model. Taken together, our data suggested that administration of BMX (HDAC8-specific inhibitor) or SAHA (pan-HDACi) may be as an efficiently strategy to prevent or cure in MPTP-induced Parkinson’s disease models. These findings provide further evidence to suggest that inhibition of HDAC8 activity may be as an important approach for therapy of Parkinson’s disease.
Keywords: NBM-T-L-BMX-OS01; Parkinson’s disease; MPTP; Histone deactylase 8 inhibitor; HDACs
Last update: 18 February 2011